Chlordiazepoxide hydrochloride; clidinium bromide - Generic Drug Details

What are the generic sources for chlordiazepoxide hydrochloride; clidinium bromide and what is the scope of patent protection?

Chlordiazepoxide hydrochloride; clidinium bromide is the generic ingredient in two branded drugs marketed by Alembic, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Chartwell Rx, Corepharma, Dr Reddys, Micro Labs, Misemer, Nuvo Pharms Inc, Teva Pharms Usa, Torrent, Winder Labs Llc, and Bausch, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

Fourteen suppliers are listed for this compound.

Summary for chlordiazepoxide hydrochloride; clidinium bromide

US Patents:	0
Tradenames:	2
Applicants:	14
NDAs:	14
Finished Product Suppliers / Packagers:	14
DailyMed Link:	chlordiazepoxide hydrochloride; clidinium bromide at DailyMed

Pharmacology for chlordiazepoxide hydrochloride; clidinium bromide

Drug Class	Anticholinergic Benzodiazepine
Mechanism of Action	Cholinergic Antagonists
Physiological Effect	Decreased Parasympathetic Acetylcholine Activity Digestive/GI System Activity Alteration GI Motility Alteration

Anatomical Therapeutic Chemical (ATC) Classes for chlordiazepoxide hydrochloride; clidinium bromide

N05BA	Benzodiazepine derivatives
N05B	ANXIOLYTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for chlordiazepoxide hydrochloride; clidinium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	215835-001	Jul 19, 2022	AB	RX	No	No
Alembic	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	216969-001	Sep 15, 2023	AB	RX	No	No
Winder Labs Llc	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	212344-001	Jul 8, 2024	AB	RX	No	No
Misemer	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	210579-001	Jul 29, 2020	AB	RX	No	No
Nuvo Pharms Inc	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	211421-001	Jul 7, 2020	AB	RX	No	No
Aurobindo Pharma Ltd	CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	216419-001	Sep 14, 2023	AB	RX	No	No

Expired US Patents for chlordiazepoxide hydrochloride; clidinium bromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	LIBRAX	chlordiazepoxide hydrochloride; clidinium bromide	CAPSULE;ORAL	012750-001	Approved Prior to Jan 1, 1982	4,316,897

Chlordiazepoxide hydrochloride; clidinium bromide Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE?

The pharmaceutical market for CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE focuses on their roles in anxiety, insomnia, and respiratory conditions. Their market size depends on usage prevalence, regulatory status, generic competition, and emerging therapeutic alternatives.

CHLORDIAZEPOXIDE HYDROCHLORIDE

This drug is a benzodiazepine used primarily for anxiety, insomnia, and muscle spasms. Its market has declined in some areas due to safety concerns, but it remains in use where prescribed.

Market Drivers

• Prescribing Trends: Declining in Western markets because of adverse effects and addiction risks. Still prescribed in some developing regions due to low cost.

• Regulatory Environment: Strict regulations limit new approvals; some countries restrict long-term use.

• Generic Availability: Widely available generics reduce prices; market share shifts towards generics.

• Alternative Therapies: Rise of selective serotonin reuptake inhibitors (SSRIs) and newer anxiolytics.

Market Size (Estimations)

• Estimated global market for benzodiazepines was approximately $1.2 billion in 2022, with CHLORDIAZEPOXIDE representing a smaller fraction due to declining prescription rates ([1]).

• North America and Europe account for over 60% of the market but show decreasing trends.

CLIDINIUM BROMIDE

This anticholinergic agent targets respiratory conditions such as COPD and chronic bronchitis. Its market varies based on disease prevalence and drug competition.

Market Drivers

• Disease Prevalence: COPD rates rising globally, especially in aging populations.

• Regulatory Approvals: Manufactured under various brand names; some formulations approved for specific inhalation therapies.

• Competition: Comes under generic competition and is often replaced by newer inhaled agents like tiotropium.

Market Size (Estimations)

• The global COPD drug market exceeded $14 billion in 2022, with clidinium bromide holding a minor share predominantly in combination therapies ([2]).

• Growth in emerging markets driven by rising urbanization and air pollution.

Competitive Landscape

Both drugs face generic penetration, impacting pricing and revenue. Clidinium bromide’s market is also affected by advances in inhaler technology and the availability of inhaled corticosteroids and long-acting beta-agonists.

Regulatory and Patent Milestones

Both drugs are off-patent, with generic versions widely available. Regulatory hurdles involve safety profile reviews and country-specific approvals. Any new formulations or delivery methods could influence future market potential.

What Is the Financial Trajectory for These Drugs?

Predicting financial trajectories involves analyzing current sales, patent status, manufacturing costs, and competitive pressures.

CHLORDIAZEPOXIDE HYDROCHLORIDE

• Expected decline in revenue due to safety concerns and regulatory restrictions.
• Off-patent status promotes generic competition with low profit margins.
• Limited pipeline innovation reduces growth prospects.
• Estimated global sales could decline at a CAGR of -3% to -5% over the next five years.

CLIDINIUM BROMIDE

• Stable income driven by demand in COPD treatment, especially in regions with less access to newer therapies.
• Market growth driven by aging populations; CAGR projected at around 1% to 2% over the next five years.
• Larger market share for combination inhalers may limit standalone drug sales but increase overall revenue if formulations are integrated.

Impact of New Therapies and Patent Expirations

Innovative therapies, especially novel inhalers and biologics, threaten future revenues. If new anxiolytics with better safety profiles emerge, CHLORDIAZEPOXIDE’s market could further shrink.

Investment Outlook

Given declining prescriptions and generic competition, investment in these drugs is unlikely to generate high returns without significant reformulation or new indications. Clidinium bromide’s outlook is slightly more optimistic, tied to respiratory disease prevalence.

Key Takeaways

• CHLORDIAZEPOXIDE HYDROCHLORIDE’s market is contracting due to safety concerns, regulatory restrictions, and competition from newer anxiolytics.
• Clidinium bromide maintains a stable niche in respiratory therapy, with slow growth driven by COPD prevalence.
• Both drugs are effectively commoditized via generics, limiting profit margins.
• Future growth depends on reformulation, new delivery systems, or new therapeutic indications.
• Regulatory landscapes are tight; market expansion options are limited.

FAQs

Q1. Are there ongoing patent protections for CHLORDIAZEPOXIDE HYDROCHLORIDE or CLIDINIUM BROMIDE?
No, both drugs are off patent, with multiple generic versions available across markets.

Q2. What therapeutic alternatives threaten the markets of these drugs?
For CHLORDIAZEPOXIDE, SSRIs and newer anxiolytics; for CLIDINIUM BROMIDE, inhalers containing tiotropium, formoterol, and combination therapies.

Q3. Which regions will drive future sales growth?
Emerging markets, particularly in Asia and Latin America, where accessibility and COPD prevalence are rising.

Q4. Can reformulating either drug unlock new revenue streams?
Yes, formulations such as sustained-release or inhalation delivery could extend market viability.

Q5. How do safety concerns impact the use of CHLORDIAZEPOXIDE HYDROCHLORIDE?
Concerns regarding dependence and adverse effects have led to regulatory restrictions, reducing long-term prescriptions.

---

References

[1] IQVIA, "Global Benzodiazepines Market Report," 2022.
[2] GlobalData, "COPD Therapeutics Market Analysis," 2022.